BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30497734)

  • 1. Prognostic value of electrocardiographic time intervals and QT rate dependence in hypertrophic cardiomyopathy.
    Robyns T; Nuyens D; Lu HR; Gallacher DJ; Vandenberk B; Garweg C; Ector J; Pagourelias E; Van Cleemput J; Janssens S; Willems R
    J Electrocardiol; 2018; 51(6):1077-1083. PubMed ID: 30497734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Patel SI; Ackerman MJ; Shamoun FE; Geske JB; Ommen SR; Love WT; Cha SS; Bos JM; Lester SJ
    Acta Cardiol; 2019 Feb; 74(1):53-58. PubMed ID: 29513133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal.
    Magrì D; Santolamazza C; Limite L; Mastromarino V; Casenghi M; Orlando P; Pagannone E; Musumeci MB; Maruotti A; Ricotta A; Oliviero G; Piccirillo G; Volpe M; Autore C
    J Cardiol; 2017 Oct; 70(4):310-315. PubMed ID: 28341542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.
    Monserrat L; Elliott PM; Gimeno JR; Sharma S; Penas-Lado M; McKenna WJ
    J Am Coll Cardiol; 2003 Sep; 42(5):873-9. PubMed ID: 12957435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
    O'Mahony C; Jichi F; Pavlou M; Monserrat L; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; McKenna WJ; Omar RZ; Elliott PM;
    Eur Heart J; 2014 Aug; 35(30):2010-20. PubMed ID: 24126876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 8. ST-segment depression as a risk factor in hypertrophic cardiomyopathy.
    Haghjoo M; Mohammadzadeh S; Taherpour M; Faghfurian B; Fazelifar AF; Alizadeh A; Rad MA; Sadr-Ameli MA
    Europace; 2009 May; 11(5):643-9. PubMed ID: 19164362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Püşüroğlu H
    Anatol J Cardiol; 2018 Sep; 20(3):165-173. PubMed ID: 30152798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
    Dinshaw L; Münch J; Dickow J; Lezius S; Willems S; Hoffmann BA; Patten M
    Clin Res Cardiol; 2018 Feb; 107(2):130-137. PubMed ID: 28965260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
    Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
    Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the association between the presence of fragmented QRS and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Akgül Ö; Uyarel H; Pusuroğlu H; Karayakalı M; Gül M; Çetin M; Satılmışoğlu H; Yıldırım A; Bakır İ
    Anatol J Cardiol; 2017 Jul; 18(1):54-61. PubMed ID: 28559533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
    Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
    Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy.
    Earle N; Ingles J; Bagnall RD; Gray B; Crawford J; Smith W; Shelling AN; Love DR; Semsarian C; Skinner JR
    J Cardiovasc Electrophysiol; 2015 Dec; 26(12):1346-51. PubMed ID: 26332198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).
    Norrish G; Ding T; Field E; Ziólkowska L; Olivotto I; Limongelli G; Anastasakis A; Weintraub R; Biagini E; Ragni L; Prendiville T; Duignan S; McLeod K; Ilina M; Fernández A; Bökenkamp R; Baban A; Kubuš P; Daubeney PEF; Sarquella-Brugada G; Cesar S; Marrone C; Bhole V; Medrano C; Uzun O; Brown E; Gran F; Castro FJ; Stuart G; Vignati G; Barriales-Villa R; Guereta LG; Adwani S; Linter K; Bharucha T; Garcia-Pavia P; Rasmussen TB; Calcagnino MM; Jones CB; De Wilde H; Toru-Kubo J; Felice T; Mogensen J; Mathur S; Reinhardt Z; O'Mahony C; Elliott PM; Omar RZ; Kaski JP
    JAMA Cardiol; 2019 Sep; 4(9):918-927. PubMed ID: 31411652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragmented QRS as a candidate marker for high-risk assessment in hypertrophic cardiomyopathy.
    Kang KW; Janardhan AH; Jung KT; Lee HS; Lee MH; Hwang HJ
    Heart Rhythm; 2014 Aug; 11(8):1433-40. PubMed ID: 24813377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy.
    Magrì D; Limongelli G; Re F; Agostoni P; Zachara E; Correale M; Mastromarino V; Santolamazza C; Casenghi M; Pacileo G; Valente F; Musumeci B; Maruotti A; Volpe M; Autore C
    Heart; 2016 Apr; 102(8):602-9. PubMed ID: 26849900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.